Innoviva Inc. (HVE)
XSTU 
Summary
HVE Chart
Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic
Innoviva is a company that is transitioning from a pure royalty-based business to a diversified healthcare company with commercial products and strategic assets. I have rated Innoviva as a buy with a probability-weighted fair value of $35.26 and a base case value of $36.92. This represents a 68.1% upside from here. GSK royalties have been a main source of revenue and are now under pressure. But new therapeutic products have been ramping up to close the gap left by royalties.
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
Innoviva (INVA) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.77 per share a year ago.
Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Innoviva Inc. (HVE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Innoviva Inc. ever had a stock split?
Innoviva Inc. Profile
| Biotechnology Industry | Healthcare Sector | Pavel Raifeld CEO | XSTU Exchange | 45781M101 CUSIP |
| US Country | 159 Employees | 30 Sep 2015 Last Dividend | 3 Jun 2014 Last Split | 5 Oct 2004 IPO Date |
Overview
Innoviva, Inc., originally known as Theravance, Inc. until its name change in January 2016, is a pharmaceutical company based in Burlingame, California. Established in 1996, the company operates both in the United States and internationally, focusing on the development and commercialization of pharmaceutical products. Innoviva is involved in strategic partnerships, including one with Sarissa Capital Management LP and a collaboration agreement with Glaxo Group Limited for the development and commercialization of once-daily products for chronic obstructive pulmonary disease and asthma. The company's efforts are primarily directed towards medicines for respiratory diseases, bacterial infections, and other specialized conditions.
Products and Services
- RELVAR/BREO ELLIPTA: A once-daily combination medicine that includes vilanterol (VI), a long-acting beta2 agonist (LABA), and fluticasone furoate, an inhaled corticosteroid (ICS). This medication is designed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- ANORO ELLIPTA: A once-daily medication combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, VI. It is indicated for the maintenance treatment of COPD.
- GIAPREZA (angiotensin II): A vasoconstrictor approved for increasing blood pressure in adults with septic or other distributive shock. It is utilized in critical care settings for managing acute drops in blood pressure.
- XERAVA (eravacycline): An antibiotic for the treatment of complicated intra-abdominal infections in adults, addressing a critical need for new options in the battle against resistant bacterial strains.
- XACDURO: A beta-lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, offering a novel approach to combating these serious infections.
In addition to these marketed products, Innoviva is also developing zoliflodacin, a late-stage product candidate, which represents a potential single oral dose cure for the treatment of uncomplicated gonorrhea, illustrating the company's commitment to addressing global public health concerns.
